Niowave to Create 70 High-Skilled Jobs with New $75M Michigan Production Facility

Niowave announced the groundbreaking of a new $75 million production facility in Lansing, Michigan, significantly expanding its manufacturing footprint and strengthening domestic supply of Actinium‑225 (Ac‑225), a critical isotope used in next‑generation targeted cancer therapies.

The new site, Niowave's second dedicated production facility in Lansing, will substantially increase capacity to support growing global demand for Ac-225 and other medical isotopes essential to emerging pharmaceutical treatments. 

The investment will create approximately 70 highly skilled jobs and further reinforce Michigan's rapidly growing leadership in advanced manufacturing and life sciences. 

"This expansion reflects our continued commitment to advancing the future of targeted alpha therapy and investing in the Lansing community," said Mike Zamaira, Chief Executive Officer of Niowave. "Actinium-225 has the potential to transform cancer treatment, and this new facility significantly strengthens our ability to deliver this critical isotope so that therapies can reach patients who need them."

"Michigan grit and innovation is proving our state is the best place to think, build, and lead the future," said Governor Whitmer. "Niowave's expansion will create more than 70 good-paying local jobs in R&D, engineering, and quality assurance, and grow our supply of medical isotopes that are critical for lifesaving cancer medicine. I'm proud of the work we've done together to grow Michigan's economy and help Michigan companies develop the next big advancement in science and technology. Congratulations to Niowave. Let's keep building the future in Michigan."